News · Heart & Metabolic
GLP-1 prescriptions for children aged 8 to 11 rose 310-fold since 2019, in records of 3.5 million kids
Obesity guidelines opened the door to weight-loss drugs for children as young as eight. US records show prescribing climbing steeply, still rare overall, and skewed toward better-off families.
- An analysis of US electronic health records covering 3,520,531 children aged 8 to 11 with obesity and no diabetes.
- Prescribing of GLP-1 drugs rose 310-fold between 2019 and 2026 but reached only 0.6% of these children.
- Rates were higher at age 11 than at age 8, and higher in girls than boys.
- Children with obesity-related conditions were far more likely to be prescribed one.
- Children from less socially vulnerable areas got them more often, raising questions about access.
Weight-loss injections moved from adults to teenagers quickly, and guidelines now let doctors consider them for children as young as eight. How often that actually happens has been guesswork.
A study in Pediatrics went through US health records for 3.5 million children aged 8 to 11 who had obesity and no diabetes. Prescriptions for GLP-1 drugs rose 310-fold in seven years, though they still reach fewer than one child in a hundred.
What obesity treatment for children involves
MedlinePlus points out that children grow at different rates, so it isn’t always easy to know when a child has obesity or is overweight, and advises parents to ask your health care provider to check whether your child’s weight and height are in a healthy range. Treatment starts with eating patterns, activity and family habits, and it suggests involving the whole family so a child does not feel singled out.
Medicines entered the picture recently. As the authors note, clinical practice guidelines for pediatric obesity management allow for consideration of glucagon-like peptide-1 receptor agonists (GLP-1RA) in children ages 8-11. Previously, no study has documented secular trends in GLP-1RA prescribing in this age group.
How the GLP-1 prescribing study was done
The researchers used Epic Cosmos, a database built from the electronic records of a large share of US health systems, and looked at repeated annual snapshots from January 2019 to June 2026. They counted prescriptions for the three weight-management drugs in this class.
Only children aged 8 to 11 with obesity and without diabetes were included, because a diabetes diagnosis would give a separate reason for the prescription. In total, the analysis covered 3 520 531 children with obesity.
Who is getting the prescriptions
The trend is steep and the base is low. Prescribing rose 310-fold from 2019 to 2026, and yet remained uncommon, reaching 0.6% of children with obesity.
Who received them varied. Rates were higher in 11-year-olds than 8-year-olds, and nearly twice as high in girls as in boys. Children with obesity-related comorbidities were substantially more likely to be prescribed GLP-1RAs, at about 189 per 10,000, and children from less socially vulnerable neighborhoods were prescribed them more often than children from more vulnerable ones.
Why prescribing patterns in children matter
Two readings sit side by side. The authors’ own is reassuring about clinical judgment: clinicians appear to be reserving GLP-1RAs for those at greatest cardiometabolic risk, meaning children who already have conditions such as high blood pressure, fatty liver or prediabetes.
The second is about fairness. Childhood obesity tends to be more common in poorer families, yet prescriptions here were more common in better-off areas. If these drugs help, the children most affected are getting them least, which usually reflects insurance, specialist access and the cost of the drugs rather than clinical need.
What a prescription database cannot show
Records show what was prescribed, not what was taken, for how long, or with what result. Weight change, side effects and whether children stayed on treatment are all outside this analysis.
Epic Cosmos covers a large share of US care but not all of it, and coding of obesity varies between practices. The study also cannot say whether prescribing to this age group is appropriate; it describes what is happening, not whether it should.
What this changes for families considering GLP-1 drugs
For parents, the useful context is that this is still rare and reserved mostly for children with additional health problems. Guidelines allow clinicians to consider these drugs at this age, and prescribing below a drug’s licensed age is off-label, a matter of clinical judgment rather than a green light.
The questions worth asking a pediatrician are the practical ones: what problem is the drug meant to solve, what happens when it stops, what side effects to watch for, and what support comes with it for eating, sleep and activity. Long-term data in children this young do not yet exist.
People also ask
What did the study find?
Among 3,520,531 children with obesity but without diabetes, 0.6% received a GLP-1 receptor agonist prescription. Rates per 10,000 were higher at age 11 (79.5) than age 8 (41.5), in girls (75.9) than boys (42.8), and in children with low social vulnerability (76.1) than high (49.2). Children with obesity-related conditions had a rate of 188.9 per 10,000. Prescribing increased 310-fold from 2019 to 2026.
Which drugs are these?
The study counted liraglutide (Saxenda), semaglutide (Wegovy) and tirzepatide (Zepbound), all licensed for weight management in some age groups and given by injection.
Are these drugs approved for children this young?
Licensed ages differ by product and country, and these drugs are not licensed for weight management this young, so such prescriptions are off-label. US pediatric obesity guidelines do allow clinicians to consider them in this age group.
Is 0.6% a lot?
It is small in absolute terms: about six in 1,000 children with obesity. The striking part is the speed of change, from near zero in 2019.
What is social vulnerability?
A measure of a neighborhood's socioeconomic disadvantage. Children from less vulnerable areas were prescribed these drugs more often, which suggests access depends partly on income and insurance.
Should a child take a GLP-1 drug?
That is a decision for a family and a pediatrician, weighing severity, other health problems, side effects and the lack of long-term data in children. This is general information rather than medical advice.